Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.44 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.44 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8079036 | 0.78 | MEN1 (0.45) | MEN1KMT2ACYP2C19KCNA4KCNA1 | |
| SCHEMBL8079031 | 0.78 | MEN1 (0.45) | MEN1KMT2ACYP2C19KCNA4KCNA1 | |
| SCHEMBL8079034 | 0.78 | MEN1 (0.45) | MEN1KMT2ACYP2C19KCNA4KCNA1 | |
| SCHEMBL27758818 | 0.77 | MEN1 (0.48) | MEN1KMT2ACYP2C19KCNA4KCNA1 | |
| SCHEMBL31546073 | 0.77 | SLC6A4 (0.46) | CYP3A4HTR2BKDM4E | |
| SCHEMBL5946282 | 0.75 | CYP2C19 (0.62) | MEN1KMT2ACYP2C19KCNA4KCNA1 | |
| SCHEMBL366283 | 0.75 | CYP2C19 (0.62) | MEN1KMT2ACYP2C19KCNA4KCNA1 | |
| SCHEMBL9405189 | 0.74 | TSHR (0.52) | CYP2C19TSHRMAPTGAACYP1A2 | |
| Cyclohexane SCHEMBL28412113 | 0.74 | MEN1 (0.46) | MEN1KMT2ACYP2C19KCNA4KCNA1 | |
| SCHEMBL5432121 | 0.74 | MEN1 (0.41) | MEN1KMT2ACYP2C19KCNA4KCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101412706-A | Novel method for preparing 1,3-dihydroxy acetone from glycerol | UNIV ZHEJIANG TECHNOLOGY (CN) | 2009-04-22 | — | — | CN | claimed |
| EP-0198388-A2 | Enterally effective biologically active peptide or protein composition, method for the production thereof, and a pharmaceutical composition containing same | Research Corporation (US) | 1986-10-22 | — | — | EP | claimed |
| WO-2025027071-A1 | MANUFACTURE OF POLYHYDROXYLAMINE VIA ELECTROLYSIS OF SUBSTRATES | BRACCO IMAGING SPA (IT) | 2025-02-06 | — | — | WO | disclosed |
| CN-109415334-B | Process for producing 1, 3-dioxane-5-ones | 花王株式会社 | 2023-12-08 | — | — | CN | disclosed |
| CN-111233817-B | Oxidation method of glycerol acetal derivative | 中国科学院大连化学物理研究所 | 2023-01-17 | — | — | CN | disclosed |
| CN-109641866-B | Process for producing glycerate | 花王株式会社 | 2022-02-25 | — | — | CN | disclosed |
| EP-3564226-B1 | METHOD FOR PRODUCING GLYCERIC ACID ESTER | KAO CORP (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3564226-B1 | METHOD FOR PRODUCING GLYCERIC ACID ESTER | KAO CORP (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-10870643-B2 | Method for manufacturing 1,3-dioxane-5-one | KAO CORPORATION (JP) | 2020-12-22 | — | — | US | disclosed |
| US-10870643-B2 | Method for manufacturing 1,3-dioxane-5-one | KAO CORPORATION (JP) | 2020-12-22 | — | — | US | disclosed |
| US-10822329-B2 | Method for producing glyceric acid ester | KAO CORPORATION (JP) | 2020-11-03 | — | — | US | disclosed |
| CN-101412706-A | Novel method for preparing 1,3-dihydroxy acetone from glycerol | UNIV ZHEJIANG TECHNOLOGY (CN) | 2009-04-22 | — | — | CN | disclosed |
| CN-101412706-A | Novel method for preparing 1,3-dihydroxy acetone from glycerol | UNIV ZHEJIANG TECHNOLOGY (CN) | 2009-04-22 | — | — | CN | disclosed |
| US-6884868-B1 | Cyclic hexapeptides having antibiotic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1173472-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064927-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | WO | disclosed |
| US-4820811-A | Amine reacted therapeutic agents | RESEARCH CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
| US-4654327-A | PEPTIDES, PROTEINS AND ANTINEOPLASTIC DRUGS FOR ENTERNAL ADMINISTRATION | RESEARCH CORP. (US) | 1987-03-31 | — | — | US | disclosed |
| EP-0198388-A2 | Enterally effective biologically active peptide or protein composition, method for the production thereof, and a pharmaceutical composition containing same | Research Corporation (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4604376-A | PROTEIN OR PEPTIDE AND SULFATE CORE WITH AMMONIUM ION | RESEARCH CORPORATION (US) | 1986-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822329-B2 | Method for producing glyceric acid ester | GK, GRHPR, DGAT1 | MEN1 2452/4885KMT2A 651/4885CYP2C19 850/4885 |
| US-10870643-B2 | Method for manufacturing 1,3-dioxane-5-one | AOX1, HAO2, DUOX1 | MEN1 1608/4885KMT2A 2233/4885CYP2C19 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.